Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-03-23 00:00:00 ET · period of report 2026-03-20 · accession 0001628280-26-020480 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | 2026-03-20 | VIR | O'Byrne Jason | EVP, CFO | J - Other | $0.00 | -2,500 | 160.1K | -2% | $0 | |
| I | 2026-03-23 | 2026-03-20 | VIR | O'Byrne Jason | EVP, CFO | J - Other | $0.00 | +2,500 | 2,500 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-20 | J | D | 2,500 | $0.00 | 160,115 | D See Footnote | — | — | (F2) The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees. |
| 2 | Common | Common Stock | 2026-03-20 | J | A | 2,500 | $0.00 | 2,500 | I | — | — |